These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36987394)

  • 21. Distinct Effects of Body Mass Index and Waist/Hip Ratio on Risk of Breast Cancer by Joint Estrogen and Progestogen Receptor Status: Results from a Case-Control Study in Northern and Eastern China and Implications for Chemoprevention.
    Wang F; Liu L; Cui S; Tian F; Fan Z; Geng C; Cao X; Yang Z; Wang X; Liang H; Wang S; Jiang H; Duan X; Wang H; Li G; Wang Q; Zhang J; Jin F; Tang J; Li L; Zhu S; Zuo W; Ma Z; Zhou F; Yu L; Xiang Y; Li L; Shen S; Yu Z
    Oncologist; 2017 Dec; 22(12):1431-1443. PubMed ID: 28912152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients.
    Cantini L; Pistelli M; Merloni F; Fontana A; Bertolini I; De Angelis C; Bastianelli L; Della Mora A; Santinelli A; Savini A; Maccaroni E; Diodati L; Falcone A; Berardi R
    Clin Breast Cancer; 2020 Feb; 20(1):e89-e98. PubMed ID: 31378534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LIPID ACCUMULATION PRODUCT, VISCERAL ADIPOSITY INDEX, AND CHINESE VISCERAL ADIPOSITY INDEX AS MARKERS OF CARDIOMETABOLIC RISK IN ADULT GROWTH HORMONE DEFICIENCY PATIENTS: A CROSS-SECTIONAL STUDY.
    Xie X; Li Q; Zhang L; Ren W
    Endocr Pract; 2018 Jan; 24(1):33-39. PubMed ID: 29144802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Body mass index, age at breast cancer diagnosis, and breast cancer subtype: a cross-sectional study.
    Brouckaert O; Van Asten K; Laenen A; Soubry A; Smeets A; Nevelstreen I; Vergote I; Wildiers H; Paridaens R; Van Limbergen E; Weltens C; Moerman P; Floris G; Neven P;
    Breast Cancer Res Treat; 2018 Feb; 168(1):189-196. PubMed ID: 29159760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Associations of obesity with osteoporosis and metabolic syndrome in Korean postmenopausal women: a cross-sectional study using national survey data.
    Kim HY; Kim Y
    Arch Osteoporos; 2019 Jun; 14(1):64. PubMed ID: 31218525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic Syndrome: does this influence breast cancer outcomes in the triple-negative population?
    Kennard K; Buckley ME; Sizer LM; Larson S; Carter WB; Frazier TG; Carp NZ
    Breast Cancer Res Treat; 2021 Feb; 186(1):53-63. PubMed ID: 33389405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Multicenter Study of the Impact of Body Mass Index (BMI) on the incidence of Pathologic Complete Response (pCR) Among Saudi Patients with locally advanced Breast cancer (LABC) post Neoadjuvant Chemotherapy (NAC).
    Al-Saleh K; Abd El-Aziz N; Ali A; Abo Zeed W; Salah T; Elsamany S; Rasmy A; El Farargy O; Husain S; Al-Rikabi A; Alsaeed E; Aldiab A; Abd El-Warith A
    Gulf J Oncolog; 2019 May; 1(30):33-42. PubMed ID: 31242980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of Interleukin 6(Il-6), Tumor Necrosis Factor Alpha (Tnf-α) and Paraoxonase 1(Pon 1) in Obese and Non-Obese Metabolic Syndrome.
    Samy K; Porwal YC; Yadav A
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does obesity interfere with anastrozole treatment? Positive association between body mass index and anastrozole plasma levels.
    Hubalek M; Oberguggenberger A; Beer B; Meraner V; Sztankay M; Oberacher H; Schubert B; Wildt L; Seeber B; Giesinger J; Kemmler G; Holzner B; Sperner-Unterweger B
    Clin Breast Cancer; 2014 Aug; 14(4):291-6. PubMed ID: 24468298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
    Williams C; Brunskill S; Altman D; Briggs A; Campbell H; Clarke M; Glanville J; Gray A; Harris A; Johnston K; Lodge M
    Health Technol Assess; 2006 Sep; 10(34):iii-iv, ix-xi, 1-204. PubMed ID: 16959170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer].
    Novoa Vargas A; Font López KC; Amador DD
    Ginecol Obstet Mex; 2011 Sep; 79(9):553-7. PubMed ID: 21966856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Basal and postprandial plasma levels of PYY, ghrelin, cholecystokinin, gastrin and insulin in women with moderate and morbid obesity and metabolic syndrome.
    Zwirska-Korczala K; Konturek SJ; Sodowski M; Wylezol M; Kuka D; Sowa P; Adamczyk-Sowa M; Kukla M; Berdowska A; Rehfeld JF; Bielanski W; Brzozowski T
    J Physiol Pharmacol; 2007 Mar; 58 Suppl 1():13-35. PubMed ID: 17443025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus.
    Boney CM; Verma A; Tucker R; Vohr BR
    Pediatrics; 2005 Mar; 115(3):e290-6. PubMed ID: 15741354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interaction between body mass index and hormone-receptor status as a prognostic factor in lymph-node-positive breast cancer.
    Chung IY; Lee JW; Lee JS; Park YR; Min YH; Lee Y; Yoon TI; Sohn G; Lee SB; Kim J; Kim HJ; Ko BS; Son BH; Ahn SH
    PLoS One; 2017; 12(3):e0170311. PubMed ID: 28248981
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pretreatment Insulin Levels as a Prognostic Factor for Breast Cancer Progression.
    Ferroni P; Riondino S; Laudisi A; Portarena I; Formica V; Alessandroni J; D'Alessandro R; Orlandi A; Costarelli L; Cavaliere F; Guadagni F; Roselli M
    Oncologist; 2016 Sep; 21(9):1041-9. PubMed ID: 27388232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association Between Visceral Adipose Tissue and Estradiol with Bone Health among Obese Women with Metabolic Syndrome.
    E Hassan N; A El-Masry S; S M El-Saeed G; Al-Tohamy M; H Thabet E; Aly MM; Mohsen M; Khalil A
    Pak J Biol Sci; 2020 Jan; 23(10):1237-1244. PubMed ID: 32981256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An observational study to examine changes in metabolic syndrome components in patients with breast cancer receiving neoadjuvant or adjuvant chemotherapy.
    Dieli-Conwright CM; Wong L; Waliany S; Bernstein L; Salehian B; Mortimer JE
    Cancer; 2016 Sep; 122(17):2646-53. PubMed ID: 27219902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. APPLICATION OF THE AACE/ACE ADVANCED FRAMEWORK FOR THE DIAGNOSIS OF OBESITY AND CARDIOMETABOLIC DISEASE STAGING IN A GENERAL POPULATION FROM 3 REGIONS OF VENEZUELA: THE VEMSOLS STUDY RESULTS.
    Nieto-Martínez R; González-Rivas JP; Ugel E; Brajkovich I; Risquez A; Garvey WT; Mechanick JI
    Endocr Pract; 2018 Jan; 24(1):6-13. PubMed ID: 29106817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.